Does treating worms in people with HIV slow progression to AIDS?

December 18, 2007

Of the 25 million people infected with HIV-1 in Africa, as many as half are thought to be co-infected with worms (helminths), and there is evidence that these worms may result in a more rapid progression of HIV infection to AIDS. Does treating these worms ("de-worming") slow down this progression"

In a new study published in the open access journal PLoS Neglected Tropical Diseases, Judd Walson and Grace John-Stewart at the University of Washington, Seattle, USA set out to answer this question. Their study found that there were simply not enough data to make any firm conclusions, and they call for larger, well-designed studies to help come to a definitive answer.

In their study, the investigators did an exhaustive search (known as a systematic review) to find every study ever conducted examining the link between being infected with worms and the progression of HIV to AIDS. In their final analysis, they included only those studies that met the researchers' pre-specified quality criteria.

There were five studies in the final analysis. All five were limited by short follow up times. Only one of these was a randomized controlled trial (RCT)--it compared the effects of treating worms in people with HIV against no treatment. The trial did find some benefit from the de-worming treatment. In patients with HIV who did not receive the de-worming treatment, their viral load (a measure of the amount of HIV in their bloodstream) went up. In contrast, the viral load of patients who were de-wormed remained stable. However, de-worming was not associated with improvements in the patients' immune status (as measured by the CD4 count) or in their clinical condition.

The four other included studies, which were observational studies rather than RCTs, also suggested that treating worms could have a beneficial effect as measured by a patient's viral load. But again these studies showed no benefit in terms of a patient's immune status or clinical condition.

"After a comprehensive review of the available literature," say the authors, "we conclude that there is not enough evidence to determine whether treating helminth infections in people with HIV is beneficial."

"There is a need for large randomized controlled trials with longer follow-up duration in order to assess the impact of de-worming on HIV-1 progression in populations with a high prevalence of both helminth and HIV-1 infection."

In a linked Expert Commentary entitled "Helminth-HIV Co-Infection: Should We De-Worm"", Professor Zwi Bentwich (Ben Gurion University, Israel) and colleagues, who were not involved in the study, examine the evidence that helminth infections play a major role in the pathogenesis of HIV-1 infection in Africa.

"Helminth infections have an ongoing prolonged and wide negative effect on the health of the population, irrespective of their effects on HIV and possibly other infections as well," say Bentwich and colleagues. "Thus, control of helminths should be pursued in large parts of the developing world without delay and should not await the results of studies on the impact of helminths on HIV or on other infections."
-end-
CITATION: Walson JL, John-Stewart G (2007) Treatment of Helminth Co-Infection in Individuals with HIV-1: A Systematic Review of the Literature. PLoS Negl Trop Dis 1(3): e102. doi:10.1371/journal.pntd.0000102

CONTACT:
Judd Walson, MD, MPH
walson@u.washington.edu
Telephone: (In Kenya) 254-721165696

Disclaimer

This press release refers to an upcoming article in PLoS Neglected Tropical Diseases. The release is provided by journal staff. Any opinions expressed in these releases or articles are the personal views of the journal staff and/or article contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLoS Neglected Tropical Diseases

PLoS Neglected Tropical Diseases (http://www.plosntds.org/) is a peer-reviewed, open-access journal devoted to the pathology, epidemiology, prevention, treatment, and control of the neglected tropical diseases, as well as public policy relevant to this group of diseases. All works published in PLoS Neglected Tropical Diseases are open access, which means that everything is immediately and freely available subject only to the condition that the original authorship and source are properly attributed. The Public Library of Science uses the Creative Commons Attribution License, and copyright is retained by the authors.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org.

PLOS

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.